Metraipolis › archive › dc_28ea39780e6b

Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses — Europe PMC PMID:41768859

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41768859
DOI: 10.17179/excli2025-9094
License (as archived): solo-consultazione
Archived: 2026-11-06T18:09:35.456Z
SHA-256 of the archived text: 2e0e5aaee572eb6a2043839900153db5def5d3b0a7efe81e18ddde01c29cc07a
Stable URL of this page: https://metraipolis.com/documento/dc_28ea39780e6b

How to cite

Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses — Europe PMC PMID:41768859 — Europe PMC (en), https://europepmc.org/article/MED/41768859 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_28ea39780e6b (Metraipolis archive dc_28ea39780e6b, sha256 2e0e5aaee572eb6a2043839900153db5def5d3b0a7efe81e18ddde01c29cc07a)

BibTeX

@misc{dc28ea39780e6b,
  title = {Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses — Europe PMC PMID:41768859},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41768859},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_28ea39780e6b; sha256 2e0e5aaee572eb6a2043839900153db5def5d3b0a7efe81e18ddde01c29cc07a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41768859. Agents can read the archived copy with the MCP tool read_document.